[Form 4] CRYO CELL INTERNATIONAL INC Insider Trading Activity

Rhea-AI Filing Summary

Cryo-Cell International (CCEL) Chairman and Co-CEO David Portnoy filed a Form 4 reporting open-market purchases of common stock. On 11/20/2025, he acquired 289 shares at $4.00 per share, and on 11/21/2025 he acquired 800 shares at $4.04 and additional shares at $4.09 and $4.10, including purchases held as custodian for his son. Following these transactions, his directly held common stock increased to 847,629 shares, with additional indirect holdings through family accounts and various entities.

The filing also lists several stock option grants over prior years with exercise prices between $4.30 and $12.27, covering amounts such as 280,000 and 50,000 underlying shares, and expirations from 2027 to 2030. Some options vest over time on specified future dates, while one grant vests in full if the company’s share price reaches $25.00 during its seven-year term.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PORTNOY DAVID

(Last) (First) (Middle)

700 BROOKER CREEK BLVD

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		A		289	A	$4	846,829	D
Common Stock	11/21/2025		A		800	A	$4.04	847,629	D
Common Stock	11/21/2025		A		677	A	$4.09	12,214	I	As Custodian for son
Common Stock	11/21/2025		A		406	A	$4.09	11,804	I	As Custodian for son
Common Stock	11/21/2025		A		273	A	$4.1	11,212	I	As Custodian for son
Common Stock								161,833	I	By Corporation(1)
Common Stock								164,182	I	By 401K
Common Stock								268,878	I	By IRA
Common Stock								107,403	I	By Spouse
Common Stock								57,306	I	By Corporation(2)
Common Stock								59,027	I	By LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$7.53							08/30/2019	08/30/2029	Common stock	26,243		26,243	D
Stock Option	$7.28							12/20/2019	12/20/2029	Common Stock	23,636		23,636	D
Stock Option	$12.27							12/22/2021(4)	12/22/2028	Common Stock	280,000		280,000	D
Stock Option	$4.77							01/03/2023(5)	01/03/2028	Common Stock	50,000		50,000	D
Stock Option	$4.3							12/23/2022	12/23/2027	Common Stock	50,000		50,000	D
Stock Option	$6.47							12/22/2023(6)	12/22/2028	Common Stock	50,000		50,000	D
Stock Option	$8.08							01/21/2025(7)	01/21/2030	Common Stock	50,000		50,000	D

Explanation of Responses:

1. Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary.

2. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.

3. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.

4. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.

5. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.

6. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

7. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.

	/s/ David Portnoy	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did David Portnoy report for Cryo-Cell International (CCEL)?

David Portnoy reported open-market purchases of Cryo-Cell common stock. On 11/20/2025 he bought 289 shares at $4.00, and on 11/21/2025 he bought additional lots at $4.04, $4.09, and $4.10 per share, including shares for a custodial account for his son.

How many CCEL shares does David Portnoy own directly after these transactions?

After the reported trades, David Portnoy directly owns 847,629 shares of Cryo-Cell International common stock. The filing also shows further indirect holdings through family accounts, corporations, an IRA, a 401(k), and an LLC.

What is David Portnoy’s role and relationship to Cryo-Cell International (CCEL)?

David Portnoy is listed as a Director, Chairman, Co-CEO, and 10% owner of Cryo-Cell International Inc. This status requires him to report changes in his beneficial ownership of the company’s securities on Form 4.

What stock options in CCEL does David Portnoy hold according to this Form 4?

The filing shows multiple stock option grants with exercise prices such as $7.53, $7.28, $12.27, $4.77, $4.30, $6.47, and $8.08, covering amounts like 26,243, 23,636, 280,000 and 50,000 underlying shares, with expirations between 2027 and 2030.

How do David Portnoy’s CCEL stock options vest?

Vesting terms vary by grant. Some options vest in tranches on specific dates, such as portions vesting on 12/22/2024, 12/22/2025, 1/2/2025, and 1/2/2026. One grant vests immediately if Cryo-Cell’s common stock price reaches $25.00 per share during its seven-year term, while others vest one-third upon issuance and one-third on later stated dates.

What indirect CCEL shareholdings does David Portnoy report?

In addition to his direct holdings, David Portnoy reports indirect ownership of Cryo-Cell shares through accounts held as custodian for his son, his spouse, corporations including PartnerCommunity, Inc. and uTIPu, Inc., retirement accounts, and an LLC and limited partnership structure in which he has controlling roles.